Adaptive Biotechnologies (ADPT) Misses Q2 EPS by 11c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts ADPT Hot Sheet
Price: $26.71 +3.53%
Revenue Growth %: -23.8%
Financial Fact:
Benefit from (provision for) income taxes: 2.06M
Today's EPS Names:
COHR, ATS, SICP, More
Revenue Growth %: -23.8%
Financial Fact:
Benefit from (provision for) income taxes: 2.06M
Today's EPS Names:
COHR, ATS, SICP, More
Join SI Premium – FREE
Adaptive Biotechnologies (NASDAQ: ADPT) reported Q2 EPS of ($0.25), $0.11 worse than the analyst estimate of ($0.14). Revenue for the quarter came in at $71.55 million versus the consensus estimate of $65.75 million.
For earnings history and earnings-related data on Adaptive Biotechnologies (ADPT) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Vertex (VERX) Tops Q3 EPS by 4c; Offers Guidance
- Relay Therapeutics, Inc. (RLAY) Tops Q3 EPS by 3c
- Solid Biosciences (SLDB) Tops Q3 EPS by 5c
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
